Evidence map›Paper›PMID 40248741›Full record

ArticleTranslational lung cancer research2025

Connecting the dots: (RANKL

Anita J W M Brouns, Iris J Robbesom-van den Berge, Sophie M Ernst, Christi M J Steendam, Wouter W Woud, Liang Wu, Anne-Marie C Dingemans, Lizza E L Hendriks, Marjolein van Driel

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05221372 (proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05221372 recruitingnot on this map

proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors

Typeobservational_patient_registrySponsorErasmus Medical CenterRan2017 to 2031Enrolled1,300ConditionsNon Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anita J W M BrounsDepartment of Respiratory Medicine, Zuyderland, Geleen, The Netherlands.
Iris J Robbesom-van den BergeDepartment of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Sophie M ErnstDepartment of Respiratory Medicine, Erasmus Medical Center Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Christi M J SteendamDepartment of Respiratory Medicine, Erasmus Medical Center Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Wouter W WoudDepartment of Neurosurgery, Brain Tumor Center, Erasmus Medical Center, The Netherlands.
Liang WuErasmus MC Transplant Institute, Department of Internal Medicine, University Medical Center, Rotterdam, The Netherlands.
Anne-Marie C DingemansDepartment of Respiratory Medicine, Erasmus Medical Center Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
Lizza E L HendriksDepartment of Respiratory Medicine, Maastricht University Medical Center+, Maastricht, The Netherlands.
Marjolein van DrielDepartment of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The biological mechanisms responsible for the different incidences of bone metastases in molecular subgroups of non-small cell lung cancer (NSCLC) are not identified. Extracellular vesicles (EVs) may play a role, as they are involved in organotrophic metastasis. Phosphorylation of epidermal growth factor receptor (EGFR) in exosomes possibly leads to an increase in receptor activator of nuclear factor κB ligand (RANKL) triggering osteoclastogenesis. In search for new biomarkers with focus on EVs and RANKL, we studied in plasma of patients with Methods: From the prospective biomarker cohort study START-TKI (NCT05221372), including patients with metastatic Results: Forty unique patients with in total 50 plasma samples (45% at initiation of osimertinib, 55% during osimertinib treatment) were included. Identification of EVs was possible in 38/40 patients, and determination of RANKL and OPG plasma levels in all samples. Of these 40 patients, 25 (63%) had bone metastases at sample collection. Both total EV and RANKL Conclusions: No association was found between the presence of bone metastases and the total concentration of EVs, RANKL

Indexed as

Bone metastasesepidermal growth factor receptor+ non-small cell lung cancer (EGFR+ NSCLC)extracellular vesicles (EVs)osteoprotegerin (OPG)receptor activator of nuclear factor κB ligand (RANKL)

Identifiers

PMID40248741
PMCPMC12000961

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.